The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | 90Y-FF-21101: a P-cadherin-targeting antibody in advanced CRC
Vivek Subbiah, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the results of a Phase I expansion study of 90Y-FF-21101, a P-cadherin targeting monoclonal antibody in advanced chemorefractory colorectal (CRC) and pancreatic-biliary cancers. Overexpression of the cell-cell adhesion protein P-cadherin has been associated with a more aggressive cancer cell phenotype, cancer stem cell properties, tumor invasion, and metastasis and therefore may prove an important target for therapy in advanced colorectal and pancreatic-biliary cancers. This novel antibody was well-tolerated and preliminary evidence suggests clinical benefit in heavily pre-treated patients with advanced colorectal cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
